Compare PICS & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PICS | RAPP |
|---|---|---|
| Founded | 2012 | 2022 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | N/A | 2024 |
| Metric | PICS | RAPP |
|---|---|---|
| Price | $11.41 | $38.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $22.00 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 301.6K | 283.7K |
| Earning Date | 05-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.65 | N/A |
| Revenue Next Year | $39.85 | N/A |
| P/E Ratio | $29.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.88 | $7.73 |
| 52 Week High | $18.49 | $42.27 |
| Indicator | PICS | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 59.14 |
| Support Level | $11.26 | $25.48 |
| Resistance Level | $14.23 | $41.33 |
| Average True Range (ATR) | 0.93 | 2.43 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 31.80 | 68.48 |
PicS NV is a digital payments company. The company operates a peer-to-peer (P2P) transfer platform that enables individuals to send money via mobile devices. It provides digital wallets, instant payments (Pix), P2P transfers, credit cards, loans, investments, insurance, and SMB payment solutions. The company has four reportable segments: Consumer Banking, Small and Medium-Sized Businesses, Audiences and Ecosystem Integration, and Institutional. The majority of the company's revenue is derived from the Consumer Banking segment, which generates revenue from various transaction activities occurring in the digital wallet, such as Pix, peer-to-peer (P2P) transfers, and bill payments.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.